Sulfapyridine

03/01/1999 - "[A case of drug induced urolithiasis composed of acetyl sulphapyridine associated with ulcerative colitis]."
01/01/1984 - "For determination of the sulphapyridine level there were used 83 sera of 57 patients with Crohn's disease or ulcerative colitis which were treated with salazosulphapyridine. "
04/01/2010 - "The practice of dosing mesalamines in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity. "
07/01/1992 - "Colonic biopsies were obtained from patients with active ulcerative colitis and organ cultured 24 hours in the absence or presence of the following drugs: sulphasalazine, sulphapyridine, 5-ASA and 4-ASA (25-100 micrograms/ml). "
01/01/1990 - "[Individualized sulfasalazine treatment of ulcerative colitis and monitoring of patient compliance by determining sulfapyridine serum concentration]."

01/01/1985 - "The higher sulphapyridine levels in synovial fluid found in this study suggest the possibility that this moiety could play a more active role in RA than it does in inflammatory bowel disease."
01/01/1981 - "Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease."
02/01/1992 - "The results of this study indicate that the vast majority of patients with inflammatory bowel disease can be managed with at least one of these four 5-ASA containing preparations and that the side-effects of sulphasalazine are multifactorial in aetiology, some being due to the parent molecule, and some to one of its two metabolites, 5-ASA and sulphapyridine."
10/01/1991 - "Sulphapyridine, which is not effective in inflammatory bowel disease inhibited malondialdehyde production at a concentration of 10(-3) M only."
05/01/1991 - "Salazopyrine, a common therapy for inflammatory bowel disease, is known to have a reversible antifertility effect in men and male rats via its metabolite, sulphapyridine. "

01/01/1984 - "For determination of the sulphapyridine level there were used 83 sera of 57 patients with Crohn's disease or ulcerative colitis which were treated with salazosulphapyridine. "
01/01/1982 - "Estimations of the serum level of sulfapyridine in 21 patients suffering from colitis ulcerosa or Crohn's disease, have been carried out. "
11/01/1994 - "One patient was receiving SSZ for Crohn's disease and was subsequently treated with olsalazine, which lacks the sulfapyridine component of SSZ. "
01/01/1981 - "In eleven pregnant patients with ulcerative colitis or Crohn's disease who were treated with sulphasalazine (SASP) the serum concentrations of SASP and sulphapyridine (SP) were measured at delivery. "
12/25/1980 - "We studied the therapeutic efficacy of sulfasalazine and its metabolites sulfapyridine and 5-aminosalicylic acid in nine patients with Crohn's disease and in 23 patients with ulcerative colitis. "

08/01/1996 - "To compare the efficacy of sulfasalazine (SSZ) with its two moieties, 5-aminosalicylic acid (ASA) and sulfapyridine (SP), in patients with active ankylosing spondylitis (AS). "
01/01/2010 - "Sulfasalazine is a prodrug composed by a molecule of 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), linked by an azo bond, which has been shown to be effective in the therapy of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease, as well as of rheumatic diseases, such as rheumatoid arthritis and ankylosing spondylitis. "

01/01/1985 - "A study was made of plasma and synovial fluid levels of sulphasalazine, one of its dissociation products--sulphapyridine and a metabolite of the latter--acetyl sulphapyridine in patients with rheumatoid arthritis (RA) who were in a steady state on sulphasalazine therapy. "
08/01/2006 - "5-ASA is the active moiety in sulfasalazine, which was initially developed for the treatment of rheumatoid arthritis more than 60 years ago, by linking 5-ASA with sulfapyridine Because many of the side effects related to sulfasalazine were found to be due to sulfapyridine, several drugs that contain 5-ASA, and lack the side-effect profile of sulfasalazine, have been developed during the last 2 decades. "
05/01/1991 - "These findings are significant since sulfapyridine is an active moiety of sulfasalazine, which is responsible for the second line of defense in the treatment of rheumatoid arthritis (RA). "
04/01/1988 - "Co-trimoxazole in rheumatoid arthritis: a comparison with sulphapyridine."
01/01/1986 - "Unless this problem can be overcome, sulphapyridine is unlikely to offer any therapeutic advantages over sulphasalazine in the treatment of rheumatoid arthritis."